MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off from China-based MicroPort Scientific Corp (HKG: 0853), has announced the successful completion of the first two clinical applications of its third-generation transcatheter aortic valve implantation (TAVI) product. This advanced medical device features a recyclable and controllable bend delivery system, which was used in two patients suffering from severe aortic valve stenosis, leading to significant symptom alleviation and recovery.
Innovative Features of the Third-Generation TAVI Product
The third-generation TAVI product is an upgraded version of CardioFlow Medtech’s second-generation TAVI product, VitaFlow Liberty. It introduces a highly innovative controllable bending function that facilitates arch crossing during surgery, making the delivery process smoother and reducing tissue damage. This feature also improves the coaxiality of the valve during pre-positioning and release, making it easier to anchor, reducing operational difficulty, and enhancing release accuracy, thereby improving the surgical success rate and effectiveness.
Clinical Benefits and Surgical Advantages
The unique spatial bending structure of the device is designed to align more closely with the human heart structure, making it suitable for various challenging anatomical structures. Additionally, the limit switch on the handle of the delivery system helps surgeons reduce the rate of intraoperative misoperation, further optimizing the surgical process. These innovations contribute to a safer and more effective procedure for patients with severe aortic valve stenosis.-Fineline Info & Tech
